Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

Java Development Kit (JDK) 25, a planned long-term support release of standard Java due in September, has reached the initial rampdown or bug-fixing phase with 18 features. The final feature ...

Chart Industries and Flowserve agreed to combine in an all-stock merger valued at ~$19B including debt, creating a differentiated leader in industrial process technologies.

Industrial companies Chart Industries Inc. and Flowserve Corp. agreed to merge in a deal valuing the combined company at about $19 billion.

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning ...

Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its first-quarter earnings call. RXRX expects several data readouts throughout 2025.

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 ...

In response to these policy shifts, Recursion announced today that its biotech accelerator Altitude Lab is launching a pre-seed venture fund to support biotech startups.

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...